Biologic and clinical evaluation of high intermittent dose all trans retinoic acid (ATRA) in refractory multiple myeloma (MM) patients (PTS).

被引：0
|
作者：
Hussein, MA [1 ]
Bocock, K [1 ]
Bloom, T [1 ]
Finke, J [1 ]
Rybicki, L [1 ]
Scott, R [1 ]
Bukowski, RM [1 ]
机构：
[1] Cleveland Clin, Ctr Canc, Cleveland, OH 44106 USA
来源：
BLOOD | 1998年 / 92卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
444
引用
收藏
页码：108A / 109A
页数：2
相关论文
共 50 条
  • [31] PHASE I TRIAL OF VORINOSTAT PLUS BORTEZOMIB (BORT) IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (MM) PATIENTS (PTS)
    Badros, Z.
    Philip, S.
    Niesvizky, R.
    Goloubeva, O.
    Harris, C.
    Zweibel, J.
    Wright, J.
    Burger, A.
    Baer, M.
    Egorin, M.
    Grant, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 258 - 258
  • [32] Clinical and laboratory evaluation of all-trans retinoic acid modulation of chemotherapy in patients with acute myelogenous leukaemia
    Seiter, K
    Feldman, EJ
    Halicka, HD
    Deptala, A
    Traganos, F
    Burke, HB
    Hoang, A
    Goff, H
    Pozzuoli, M
    Kancherla, R
    Darzynkiewicz, Z
    Ahmed, T
    BRITISH JOURNAL OF HAEMATOLOGY, 2000, 108 (01) : 40 - 47
  • [33] Pharmacological dose ascorbic acid administration in relapsed refractory multiple myeloma patients
    Bolaman, Ali Zahit
    Turgutkaya, Atakan
    Kucukdiler, Hilal Eroglu
    Selim, Cem
    Yavasoglu, Irfan
    LEUKEMIA RESEARCH REPORTS, 2021, 16
  • [34] Hemostatic changes in acute promyelocytic leukemia (APL) patients during all-trans-retinoic acid (ATRA) therapy
    Garcia, MC
    Royo, M
    Marco, P
    Roldan, V
    Fernandez, P
    Espana, F
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS512 - PS512
  • [35] Fibrinolysis in patients with acute promyelocytic leukemia in complete remission during all-trans Retinoic acid (ATRA) therapy
    Parma, M
    Belotti, D
    Piazza, M
    Rivolta, GF
    Pogliani, EM
    THROMBOSIS AND HAEMOSTASIS, 1997, : PS969 - PS969
  • [36] A phase IIb trial of all-trans retinoic acid (ATRA) combined with bryostatin 1 (BRYO) in patients (pts) with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
    Stone, R
    DeAngelo, D
    Galinsky, I
    Yang, XP
    Daftary, F
    Xu, GG
    Liou, S
    BLOOD, 2000, 96 (11) : 265B - 265B
  • [37] HYPERCALCEMIA AND INCREASED SERUM INTERLEUKIN-6 LEVELS INDUCED BY ALL-TRANS-RETINOIC ACID IN PATIENTS WITH MULTIPLE-MYELOMA
    NIESVIZKY, R
    SIEGEL, DS
    BUSQUETS, X
    NICHOLS, G
    MUINDI, J
    WARRELL, RP
    MICHAELI, J
    BRITISH JOURNAL OF HAEMATOLOGY, 1995, 89 (01) : 217 - 218
  • [38] Phase II trial of all-trans retinoic acid (ATRA) in the treatment of relapsed/refractory mycosis fungoides/sezary syndrome (MF/SS).
    Siegel, RS
    Martone, B
    Guitart, J
    Samuelson, E
    Rosen, ST
    Kuzel, TM
    BLOOD, 1999, 94 (10) : 97A - 97A
  • [39] Biological and Clinical Significance of Undetectable Circulating Tumor Cells (CTCs) in Patients (Pts) with Multiple Myeloma (MM)
    Garces, Juan-Jose
    Termini, Rosalinda
    Martin-Sanchez, Esperanza
    Lasa, Marta
    Perez, Jose J.
    Gutierrez, Norma C.
    Fernandez, Manuela
    Jose Calasanz, Maria
    Rosinol, Laura
    Hernandez Garcia, Miguel Teodoro
    Oriol, Albert
    Sureda Balari, Anna Maria
    Perez Montana, Albert
    Ocio, Enrique M.
    Casanova Espinosa, Maria
    Prosper, Felipe
    Martinez-Lopez, Joaquin
    Labrador, Jorge
    Gonzalez Garcia, Esther
    Rios, Rafael
    Escalante, Fernando
    Bargay, Joan
    Cabezudo, Elena
    Cabanas, Valentin
    Weinhold, Niels
    Roccaro, Aldo
    Avet-Loiseau, Herve
    Orfao, Alberto
    Blade Creixenti, Joan
    Victoria Mateos, Maria
    Lahuerta Palacios, Juan Jose
    San-Miguel, Jesus
    Cedena, Maria T.
    Puig, Noemi
    Paiva, Bruno
    BLOOD, 2023, 142
  • [40] Intermittent intermediate dose arabinosilcytosine (ID ara-C) preceded by a fludarabine (FAMP) minimum effective dose and all-trans retinoic acid (ATRA) in relapsed or resistant acute myeloid leukaemia (AML).
    Montillo, M
    Tedeschi, A
    Cafro, AM
    Castagnola, C
    Muti, G
    Nosari, AM
    Lazzarino, M
    Morra, E
    BLOOD, 2001, 98 (11) : 218B - 218B
12345